Jessner lymphocytic infiltration of the skin (JLIS) is the term used to describe a rare, benign cutaneous condition characterized by papular or plaque-like eruptions that commonly involve sun-exposed areas such as face, neck, and trunk. The eruptions are erythematous, non-scaly, and can also be annular. This disease has an indolent course, lasting weeks to months, and as the eruptions expand peripherally, they can sometimes exhibit central clearing or healing. The eruptions then clear spontaneously, or with the aid of medications, without sequelae but frequently recur. The lesions are usually asymptomatic. However, some patients have complained of burning and pruritus.
This disease is diagnosed by biopsy revealing perivascular and periadnexal clusters of plasmacytoid monocytes within the dermis, sometimes extending into the subcutaneous tissue. These cells, also known as plasmacytoid dendritic cells, play a vital role in the induction of autoimmune diseases and other skin diseases. While their presence, along with an inappropriate CD8+ T cell predominant lymphoid infiltrate, provides a definitive diagnosis of JLIS, the cause of this disorder remains unknown. However, there remains the possibility of hereditary and autoimmune components.
JLIS, also known as benign lymphocytic infiltration of the skin, Jessner-Kanof syndrome, and benign chronic T-cell infiltrative disease, was first described in 1953 by Max Jessner and Norman Kanof.
In 1969, the disease was included under the umbrella term cutaneous lymphoid hyperplasia along with lymphocytoma cutis and malignant lymphomas used to encompass skin diseases with lymphocytic infiltrates. There is still debate about whether this disease is a unique entity or part of a spectrum of cutaneous diseases, including discoid lupus erythematosus, polymorphous light eruption, and possibly malignant lymphoma. However, there is no conclusive evidence of progression to any of the diseases mentioned above, although there are case reports of patients with concurrent manifestations.
The etiology of Jessner lymphocytic infiltration of the skin (JLIS) remains unknown. However, there are numerous proposed etiologies. There may be a genetic/hereditary component due to multiple reported familial cases of the disease. Another possible etiology is autoimmune. The plasmacytoid dendritic cells present in JLIS are known to play a role in autoimmune diseases such as systemic lupus erythematosus. One hypothesis is that JLIS may be an early cutaneous manifestation of SLE or even a progression of lupus erythematosus timidus.
The suppression of natural kill cell cytolytic activity suggests an alteration in immunoregulatory pathways similar to those in neoplastic and endocrine disorders.
Further studies report photosensitivity as a trigger for JLIS, causing this disease to be linked to polymorphous light eruption. The fact that the distribution of eruptions is usually in sun-exposed areas serves as further support for this possible etiology. Finally, there are drug-induced cases, primarily by angiotensin-converting enzyme inhibitors and immunosuppressive therapies such as etanercept, ustekinumab, leflunomide, and glatiramer acetate. Less common causes described in case reports include duloxetine, HIV, and Borrelia burgdorferi infection.
Jessner lymphocytic infiltration of the skin (JLIS) is a rare condition with unknown incidence and prevalence in both the U.S. and worldwide. The disease onset is usually between 30 and 50 years of age; however, there are cases reported in children, though they are less common. Originally thought to be male predominant, more recent studies show no gender bias, and there is also no evidence of racial predominance.
Jessner lymphocytic infiltration of the skin (JLIS) used to represent a CD8+ polyclonal reactive skin disorder. The pathophysiology is yet unknown; however, the most popular theory involves plasmacytoid dendritic cell-directed migration of lymphocytes leading to an inappropriate accumulation of CD8+ T lymphocytes in the dermis. The etiology of the presence of clusters of plasmacytoid dendritic cells in the affected perivascular and periadnexal regions is yet unknown.
Histopathological examination of skin biopsies reveals normal epidermis without atrophy, follicular plugging, basal vacuolar change, or basement membrane thickening. There are dense superficial and deep perivascular and periadnexal CD8+ T cell lymphocytes infiltrates within the dermis that sometimes extends into the subcutaneous tissue and can also be perifollicular. While T cells are noted to be more peripheral, B cells expressing follicular center differentiation are found close to superficial vessels. There are also perivascular and periadnexal clusters of plasmacytoid monocytes within the dermis.
Plasmacytoid monocytes, also called plasmacytoid dendritic cells, are larger than lymphocytes with a pale nucleus and a relatively large single nucleolus. These cells are usually scattered throughout the dermis. When eruptions are present, there is also an increase in circulating immune complexes, which typically normalize with the resolution of the eruption. There is also a depressed natural killer cell cytolytic function.
Patients presenting with Jessner lymphocytic infiltration of the skin (JLIS) commonly report asymptomatic, non-scaly, erythematous solitary or numerous plaques or papules in sun-exposed areas (face, neck, and trunk) that have been present for weeks to months. History may reveal the onset or exacerbation of the lesions following sun exposure. The lesions may have cleared spontaneously without sequelae and reoccurred at the original site or in previously unaffected areas. While the lesions are typically asymptomatic, some patients do experience burning or pruritis. Since some case reports suggest a pattern of inheritance, a history should include whether other family members have had similar lesions. Also, as there is a suspected autoimmune component, patients should be asked about personal and family history of autoimmune disease.
On physical examination, the lesions are well-demarcated and can appear annular or seen to be expanding peripherally. The surface of the lesions is non-scaly without evidence of follicular plugging or atrophy. The lesions are arranged in crescents of rings ranging from 2 mm to 2 cm in diameter. A thorough skin examination should be performed as patients can have multiple lesions. The most frequent areas of occurrence are the malar area of the face and the upper back. However, lesions can be found in any area, including the forehead, neck, mastoid region, arms, legs, and trunk.
Basic laboratory studies, including complete blood count and urinalysis, should be done.
Autoimmune Workup: Antinuclear antibodies (ANA), and erythrocyte sedimentation rate (ESR) should be done first. If positive, recommend testing for systemic lupus erythematosus (SLE) with anti-smith and double-stranded DNA antibodies, antiphospholipid syndrome with lupus anticoagulant and anti-cardiolipin antibodies and anti-apolipoprotein antibodies, Sjogren syndrome with anti-Ro and anti-La antibodies, rheumatoid arthritis with rheumatoid factor and anti-citrullinated protein antibodies.
Other Tests: UVA and UVB provocative photo testing.
Diagnostic Testing: Skin biopsy with hematoxylin and eosin (H&E) staining, direct immunofluorescence (DIF), Alcian blue staining with pH 2.5 for dermal mucin and cytology.
There is no effective therapy for Jessner lymphocytic infiltration of the skin (JLIS). Current treatment involves mainly topical steroids such as hydrocortisone, triamcinolone, betamethasone, and prednisone, or antimalarials like hydroxychloroquine. However, many patients elect not to undergo treatment for a benign condition when the main medications used have dangerous side effects.
First-line therapy is topical and intralesional steroids. In cases in which photosensitivity is relevant, antimalarials are more effective. Tacrolimus, thalidomide, etretinate, methotrexate, oral auranofin, and proquazone have also been beneficial according to some case reports.
Cosmetic camouflage, photoprotection, and excision of small lesions can eliminate or mask the appearance of the disease. Other less common treatment options include laser therapy, photodynamic therapy, and cryotherapy.
Jessner lymphocytic infiltration of the skin (JLIS) is one of a group of conditions characterized histologically by a lymphocytic infiltrate in the dermis. The following four conditions, along with JLIS, are referred to as the 5 L’s:
Polymorphous Light Eruption (PLE)
Discoid Lupus Erythematosus/Lupus Erythematosus Tumidus
Well-Differentiated Lymphocytic Lymphoma
Other differential diagnoses are:
Cutaneous lymphoid hyperplasia
Reticular erythematous mucinosis, it has positive Alcian blue staining for dermal mucin, which is negative in JLIS
As a benign condition that may resolve spontaneously with no residual sequelae, Jessner lymphocytic infiltration of the skin (JLIS) has an excellent prognosis and is not associated with increased mortality.
Jessner lymphocytic infiltration of the skin (JLIS) can affect the periorbital skin, resulting in severe cicatricial ectropion.
Jessner lymphocytic infiltration of the skin (JLIS) requires a multidisciplinary approach for the best outcomes. A dermatologist should be consulted, as well as a plastic surgeon is needed for cosmetic camouflage. If autoimmune testing is positive, a rheumatologist should also be taken on board.
With no known etiology, there are no effective preventative measures for Jessner lymphocytic infiltration of the skin (JLIS). However, since photosensitivity is a possible trigger for JLIS, patients are advised to avoid sun exposure and use photoprotection.
Due to the complication of ectropion, patients with periorbital lesions should be monitored closely.
Lastly, for patients using medical therapy such as topical steroids and antimalarials, regular follow-up is required to monitor for side-effects like skin atrophy.
The most critical aspect of the management of Jessner lymphocytic infiltration of the skin (JLIS) involves its diagnosis and treatment. JLIS is a rare disorder, and while it is a benign condition with a good prognosis, once a lesion is identified, other more emergent conditions such as lymphoma must be excluded. A dermatologist performs the task of biopsy and a pathologist with the assistance of laboratory technologists and other support staff members to analyze the sample to confirm the diagnosis with immunohistology.
Holistic care involves close collaboration between the patient, caretakers, and a team of medical professionals. The team may include a rheumatologist if an autoimmune component is present, and if multiple family members are affected, it would be best to counsel the family as a unit about the likelihood of a genetic component to the disease.
Once the diagnosis of JLIS is confirmed, it becomes essential to educate the patient about treatment options, based on the presence of risk factors such as photosensitivity, and empower them to lead the team in developing a treatment plan that best suits his/her needs. It is also possible that treatment may not be useful for every patient, and they must be aware of this.
Depending on the patient's treatment plan, a plastic surgeon may be involved as well. Effective management of this disease requires excellent communication between the interprofessional team. If the patient chooses medical therapy, they should be monitored closely for side effects. Regardless, once diagnosed with JLIS, patients should have regular skin examinations coordinated between the patient, caretakers, primary care providers, dermatologists, and any other medical personnel involved in the patient's care. Close attention should be paid to periorbital lesions as these can develop into ectropion. [Level 1]
|||Poenitz N,Dippel E,Klemke CD,Qadoumi M,Goerdt S, Jessner's lymphocytic infiltration of the skin: a CD8 polyclonal reactive skin condition. Dermatology (Basel, Switzerland). 2003; [PubMed PMID: 14571070]|
|||Tomasini D,Mentzel T,Hantschke M,Cerri A,Paredes B,Rütten A,Schärer L,Kutzner H, Plasmacytoid dendritic cells: an overview of their presence and distribution in different inflammatory skin diseases, with special emphasis on Jessner's lymphocytic infiltrate of the skin and cutaneous lupus erythematosus. Journal of cutaneous pathology. 2010 Nov; [PubMed PMID: 20659210]|
|||Konttinen YT,Reitamo S,Ranki A,Segerberg-Konttinen M, T lymphocytes and mononuclear phagocytes in the skin infiltrate of systemic and discoid lupus erythematosus and Jessner's lymphocytic infiltrate. The British journal of dermatology. 1981 Feb; [PubMed PMID: 6971117]|
|||Toonstra J,Wildschut A,Boer J,Smeenk G,Willemze R,van der Putte SC,Boonstra H,van Vloten WA, Jessner's lymphocytic infiltration of the skin. A clinical study of 100 patients. Archives of dermatology. 1989 Nov; [PubMed PMID: 2684021]|
|||Lipsker D,Mitschler A,Grosshans E,Cribier B, Could Jessner's lymphocytic infiltrate of the skin be a dermal variant of lupus erythematosus? An analysis of 210 cases. Dermatology (Basel, Switzerland). 2006; [PubMed PMID: 16778421]|
|||Rémy-Leroux V,Léonard F,Lambert D,Wechsler J,Cribier B,Thomas P,Adamski H,Marguery MC,Aubin F,Leroy D,Bernard P, Comparison of histopathologic-clinical characteristics of Jessner's lymphocytic infiltration of the skin and lupus erythematosus tumidus: Multicenter study of 46 cases. Journal of the American Academy of Dermatology. 2008 Feb; [PubMed PMID: 18083273]|
|||Akasu R,Kahn HJ,From L, Lymphocyte markers on formalin-fixed tissue in Jessner's lymphocytic infiltrate and lupus erythematosus. Journal of cutaneous pathology. 1992 Feb; [PubMed PMID: 1556268]|
|||Pereira A,Ferrara G,Calamaro P,Cota C,Massone C,Boggio F,Prieto-Torres L,Cerroni L, The Histopathological Spectrum of Pseudolymphomatous Infiltrates in Cutaneous Lupus Erythematosus. The American Journal of dermatopathology. 2018 Apr; [PubMed PMID: 28654469]|
|||Ashworth J,Morley WN, Jessner and Kanof's lymphocytic infiltration of the skin: a familial variant. Dermatologica. 1988; [PubMed PMID: 3169334]|
|||Abbad N,Lanal T,Brenuchon C,Morel G,Deprez X, Etanercept-Induced Lymphocytic Infiltration of Jessner-Kanof. Arthritis [PubMed PMID: 29024536]|
|||Guarneri C,Lentini M,Polimeni G,Giuffrida R,Cannavò SP, Ustekinumab-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and lupus erythematosus tumidus. British journal of clinical pharmacology. 2016 Apr; [PubMed PMID: 26616890]|
|||Sparsa L,Afif N,Goetz J,Sordet C,Chatelus E,Lipsker D,Sibilia J, Jessner-Kanof disease induced by leflunomide: a dermal variant of cutaneous lupus? Rheumatology international. 2011 Feb; [PubMed PMID: 19823837]|
|||Demirbaş A,Çelik ZE, Jessner's lymphocytic infiltration as a symptom of Immune Reconstitution Inflammatory Syndrome in an HIV-infected patient: A case report. Dermatologic therapy. 2020 May 21; [PubMed PMID: 32436645]|
|||Petersen MP,Vestergaard V,Bygum A, Jessner lymphocytic infiltration - rare in childhood. Dermatology online journal. 2017 Oct 15; [PubMed PMID: 29469790]|
|||Higgins CR,Wakeel RA,Cerio R, Childhood Jessner's lymphocytic infiltrate of the skin. The British journal of dermatology. 1994 Jul; [PubMed PMID: 8043427]|
|||Braddock SW,Kay HD,Maennle D,McDonald TL,Pirruccello SJ,Masih A,Klassen LW,Sawka AR, Clinical and immunologic studies in reticular erythematous mucinosis and Jessner's lymphocytic infiltrate of skin. Journal of the American Academy of Dermatology. 1993 May; [PubMed PMID: 8496412]|
|||Adamski H,Labrousse AL,Sparsa A,Leonard F,Le Gall F,Labrousse F,Ollivier I,Bonnetblanc JM,Chevrant-Breton J,Bedane C,Bernard P, [Positive photobiological investigation in Jessner's lymphocytic infiltration of the skin]. Annales de dermatologie et de venereologie. 2002 Dec; [PubMed PMID: 12536173]|
|||Ralfkiaer E,Lange Wantzin G,Mason DY,Stein H,Thomsen K, Characterization of benign cutaneous lymphocytic infiltrates by monoclonal antibodies. The British journal of dermatology. 1984 Dec; [PubMed PMID: 6391533]|
|||Awotesu S,Dubois V,El-Hindy N,Watts M, Jessner's lymphocytic infiltrate: a rare cause of lid ectropion. BMJ case reports. 2010; [PubMed PMID: 22347890]|